We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.61%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.9B
AUM Growth
-$300M
Cap. Flow
+$226M
Cap. Flow %
7.79%
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$145M
2
ARVN icon
Arvinas
ARVN
+$81.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$58.7M
4
RVMD icon
Revolution Medicines
RVMD
+$58.5M
5
ALLO icon
Allogene Therapeutics
ALLO
+$39.8M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$103M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.2M
3
PCVX icon
Vaxcyte
PCVX
+$31.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$24M
5
EXEL icon
Exelixis
EXEL
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
2 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
51
Orchestra BioMed
OBIO
$222M
$3.98M 0.14%
400,000
– –
ERAS icon
52
Erasca
ERAS
$6.53B
$3.78M 0.13%
678,441
– –
LENZ
53
LENZ Therapeutics
LENZ
$156M
$3.2M 0.11%
166,026
+19,700
+13% +$439K
NUVB.WS
54
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$3.12M 0.11%
963,333
– –
CLDX icon
55
PUT
Celldex Therapeutics
CLDX
$2.78B
$3.11M 0.11%
+115,200
New +$3.35M
SPRY icon
56
ARS Pharmaceuticals
SPRY
$640M
$2.44M 0.08%
575,359
+245,822
+75% +$857K
TPST icon
57
Tempest Therapeutics
TPST
$15.2M
$2.22M 0.08%
+79,328
New +$3.08M
KNTE
58
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.21M 0.08%
175,000
– –
EUCR
59
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$1.98M 0.07%
200,000
– –
BLSA
60
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.98M 0.07%
200,000
– –
FVAM
61
DELISTED
5:01 Acquisition Corp
FVAM
$1.98M 0.07%
200,000
– –
VERV
62
DELISTED
Verve Therapeutics
VERV
$1.51M 0.05%
98,593
– –
DYN icon
63
Dyne Therapeutics
DYN
$3.88B
$1.48M 0.05%
215,000
– –
ARYD
64
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.47M 0.05%
150,000
– –
OLMA icon
65
Olema Pharmaceuticals
OLMA
$991M
$1.44M 0.05%
+353,701
New +$1.12M
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
$1.44M 0.05%
12,438
-625
-5% -$58.8K
CNTA
67
DELISTED
Centessa Pharmaceuticals
CNTA
$1.42M 0.05%
292,320
-162,225
-36% -$1.04M
ADVM
68
DELISTED
Adverum Biotechnologies
ADVM
$1.26M 0.04%
104,670
– –
KRON
69
DELISTED
Kronos Bio
KRON
$1.19M 0.04%
326,780
– –
TMPM
70
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$993K 0.03%
100,000
– –
EUCRW
71
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$660K 0.02%
+66,666
New +$10.7K
FLACW
72
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$658K 0.02%
66,665
– –
PRDS
73
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$614K 0.02%
200,000
– –
PRAX icon
74
Praxis Precision Medicines
PRAX
$8.49B
$515K 0.02%
+14,007
New +$1.49M
OMEG
75
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$493K 0.02%
50,000
– –
1 2
3
4 5

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2022 Portfolio in Review

As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital deployed $226M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.

  • EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
  • EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
  • EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
  • EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
  • EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
  • EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.